MARKET

ATHX

ATHX

Athersys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.790
-0.080
-4.28%
After Hours: 1.740 -0.05 -2.79% 18:56 10/19 EDT
OPEN
1.880
PREV CLOSE
1.870
HIGH
1.910
LOW
1.790
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
4.380
52 WEEK LOW
1.130
MARKET CAP
353.35M
P/E (TTM)
-5.3641
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each.
Seekingalpha · 10/03 20:21
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Zacks · 09/29 13:53
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
Zacks · 09/24 18:29
Return On Capital Employed Overview: Athersys
During Q2, Athersys's (NASDAQ: ATHX) reported sales totaled $84.00 thousand. Despite a 16.36% in earnings, the company posted a loss of $18.34 million. Athersys collected $0.00 in revenue during Q1, but reported earnings showed a $15.76 million loss.What Is Return On Capital Employed? Return on Capital
Benzinga · 09/23 14:57
NKE, WDC among premarket gainers
SPI Energy (SPI) +56% after launching new EV Company.MediciNova (MNOV) +36% on positive intranasal COVID-19 vaccine data.vTv Therapeutics (VTVT) +20% on positive clinical study results supporting the safety and efficacy of TTP399.Athersys (ATHX) +13% after FDA grants RMAT
Seekingalpha · 09/23 12:19
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 09/23 12:05
Athersys cell therapy nabs accelerated review in U.S. for acute respiratory distress syndrome
The FDA designates Athersys' (ATHX) MultiStem cell therapy a Regenerative Medicine Advanced Therapy ((RMAT)) for the potential treatment of acute respiratory distress syndrome ((ARDS)).RMAT status includes all the benefits of
Seekingalpha · 09/23 10:38
Athersys Announces FDA Has Granted RMAT Designation To MultiStem Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
ARDS program well-positioned for an expedited path to commercialization with RMAT and Fast Track designation Athersys, Inc., a leading regenerative medicine company in late-stage clinical development, announced today
Benzinga · 09/23 10:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHX. Analyze the recent business situations of Athersys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHX stock price target is 7.40 with a high estimate of 11.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 183
Institutional Holdings: 62.02M
% Owned: 31.42%
Shares Outstanding: 197.40M
TypeInstitutionsShares
Increased
52
21.45M
New
54
2.17M
Decreased
19
1.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Chief Executive Officer/Director
Gil Van Bokkelen
President/Chief Operating Officer
William Lehmann
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Senior Vice President - Finance
Laura Campbell
Senior Vice President
Maia Hansen
Lead Director
Lee Babiss
Director
Hardy Kagimoto
Independent Director
Ismail Kola
Independent Director
Lorin Randall
Independent Director
Jack Wyszomierski
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATHX
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Athersys Inc stock information, including NASDAQ:ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.